N/A N=77 Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration
Pain
Primary: Discomfort With Intranasal Midazolam Administration — 3; 8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
Phase 2 N=9 An Open-label Extension Study of PSMA ADC 2301 in mCRPC
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 67; 33; 33; 0 % of responders
N/A N=42 Effect of Levodopa on Postural Motor Learning in Parkinson Disease
Parkinson Disease
Primary: Change in Movement of Center of Mass (COM) After Postural Perturbation — 0.31; 0.28; 0.32; 0.26 meters
Phase 2 N=46 Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Proportion of Confirmed Tumor Responses (Complete or Partial Response) — 0.08; 0.05 proportion
Phase 3 N=871 A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
Involutional Osteoporosis
Primary: Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry (DXA) at End of Study — 5.07; 3.36…
Phase 3 N=420 Add-on to Thiazolidinedione (TZD) Failures
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -0.42; -0.82; -0.97 % of hemoglobin — p=0.0007
Phase 2 N=119 A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 29; 32; 11; 21 % of responders
Phase 2 N=54 Topical Anesthetic Use In Pessary Management
Pain
Primary: VAS Score at the Time of Pessary Removal Adjusting for Baseline Pain — 1.76; 3.81 Centimeters — p=.02
Phase 2 N=194 Study to Evaluate the Safety and Efficacy of CAT-354
Asthma
Primary: Change From Baseline in the Mean Asthma Control Questionnaire (ACQ) Score at Day 92 — 2.63; 2.72; 2.62; 2.72 units on a scale — p=0.573
Phase 2 N=92 Radiation Therapy in Treating Young Patients With Gliomas
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Phase 2 N=55 Study of Breast Cancer Prevention by Letrozole in High Risk Women
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92
Phase 3 N=1,281 A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Crohn's Disease · Colitis · IBD
Primary: Number of Participants With Clinical Remission at Week 44 — 47; 63; 68 participants — p=0.040
Phase 3 N=1,095 A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
Breast Cancer
Primary: Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment — 63.3; 64.3; 59.8 percentage of participants
Phase 3 N=103 Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries
Soft Tissue Surgical Bleeding
Primary: Percentage of Subjects Achieving Hemostasis Within 4 Minutes After Treatment Start — 82.8; 77.8 percentage of participants